Select Page

Home / News / BioBlast® / Biosimilar Deals 2021

EXPLORE OUR

Biosimilars Deals 2021

Explore our interactive biosimilar news updates, collating tailored reports by brand, INN, originator/biosimilar applicant, litigation, region, or date. Alternatively, review our weekly BioBlast updates below.

Opposing a Trade Mark or Defending Your Own – The Essential Guide. Free eBook.

Trade mark disputes can arise when a new application is considered too similar to an existing brand, or raises concerns about ownership, reputation or bad faith.  Australia has a formal opposition process that allows businesses and brand owners to challenge a trade mark application before it proceeds to registration.  However, the process involves strict rules, evidence requirements and deadlines.

Recent high-profile disputes, including Eminem vs Swim Shady (2026) and Katie Perry vs Katy Perry (2026), highlight the importance of protecting brand identity.  Trade mark conflicts also arise between Australian businesses, even when the businesses operate in different parts of the market, as illustrated by the dispute between Mars Australia and Katong Club over the KAN TONG and KATONG HOUSE marks.  These all highlight how brand protection issues can extend across businesses, industries and international markets.

If you are considering opposing a trade mark application, or defending your own, do you know what happens after a Notice of Intention to Oppose is filed?  What evidence will you need?  Can you negotiate a resolution without proceeding to a hearing?  And what options are available if you disagree with a decision?

Our free eBook explains the Australian trade mark opposition framework and outlines the key steps involved.  Designed for businesses, brand owners, in-house counsel and legal professionals, it provides practical insight into the process of challenging or defending a trade mark application.

Download the free guide to better understand your options and the process before a dispute arises.

 

 

Pearce IP can assist with the clearance, protection and management of new product and corporate brands in Australia, New Zealand and internationally. Use our Contact Form or email us at info@pearceIP.law or call Australia Tel: +61 (0) 2 9023 9988 or New Zealand Tel: +64 (4) 886 1199.


 

About Pearce IP

Pearce IP is a privately owned/independent, specialist, life-sciences focussed, intellectual property/law firm offering lawyers and attorneys in Australia and New Zealand.

Our lawyers and attorneys specialise in pharma, biopharma, biotech, ag-tech, food-tech, med-tech, although our work is broader than these industries.

Pearce IP and its leaders are ranked in every notable legal directory including: Chambers & Partners, Legal 500, IAM Patent 1000, IAM Strategy 300, MIP IP Stars, Doyles Guide, WTR 1000, Best Lawyers, WIPR Leaders, Best Law Firms, among others. In 2025, Pearce IP was honoured by Australasian Lawyer and New Zealand Lawyer as a Top Specialist Firm, 5 Star Employer of Choice, and the “Standout Winner” for Inclusion and Culture (<100 employees).  

Pearce IP is the only leading IP firm in Australia and New Zealand with a female founder, and is certified by WEConnect International as women owned.

 

Naomi Pearce

Naomi Pearce

CEO, Executive Lawyer (AU, NZ), Patent & Trade Mark Attorney (Trans Tasman)

Naomi is the CEO and Founder of Pearce IP, and is one of ANZ’s leading IP practitioners. Naomi is a market leading, strategic, commercially astute, patent lawyer, patent attorney and trade mark attorney, with over 29 years’ experience, and a background in molecular biology/biochemistry.

Ranked in virtually every notable legal directory, highly regarded by peers and clients, Naomi is renowned for her successful and elegant IP/legal strategies focussing on complex/multijurisdictional litigation, global FTO, and strategic advice.  Among other awards, Naomi is the 2026 Lexology Client Choice Winner for Patents, the 2024 Lawyers Weekly Women in Law “Executive of the Year”, the 2023 Lawyers Weekly “IP Partner of the Year”, the 2022 Lexology Client Choice Winner for Life Sciences, the 2022 Asia Pacific Women in Business Law “Patent Lawyer of the Year”, and the 2021 Lawyers Weekly Women in Law “Partner of the Year”.  Ranked in Chambers Asia Pacific, Chambers Global,  IAM Patent 1000, IAM Strategy 300, is a MIP “Patent Star”, and is recognised as a WIPR Leader for patents and trade marks.

Pearce IP is the premier life sciences focussed firm in ANZ.  Commencing in 2017. Pearce IP is the 2025 Australasian Lawyer and NZ Lawyer 5-Star Employer of Choice & “Standout Winner” for Inclusion and Culture (<100 employees).  In 2021, Pearce IP was the Lawyers Weekly Australian Law Awards IP Team of the Year.

Sally Paterson

Sally Paterson

Executive, Lawyer (NZ), Patent & Trade Mark Attorney (AU, NZ)

Sally is a senior Trans-Tasman Patent and Trade Mark Attorney, and a New Zealand registered lawyer with over 20 years’ experience in IP.  Sally’s particular expertise is in life sciences, drawing from her background in biological sciences. Sally is well respected in the New Zealand IP community for her broad ranging skills in all aspects of intellectual property advice, protection and enforcement. Sally has extensive experience securing registration for patents, designs and trade marks in New Zealand, Australia and internationally, providing strategic infringement, validity and enforceability opinions, acting in contentious disputes including matters before the courts of New Zealand and before IPONZ and IP Australia, and advising on copyright and consumer law matters.

Snowballs and Spritz Spark Product Naming Disputes

From Christmas chocolates in the UK to non-alcoholic drinks in Australia, familiar words can become a source of brand conflict and broader online commentary.

Familiar names under scrutiny

Can you be sued for using a product name that sounds descriptive?

Potentially. A business may face allegations of trade mark infringement even where a product name appears descriptive or commonly used. Whether infringement occurs depends on factors such as how the term is used, the goods involved, and whether the word is being used as a trade mark. As the recent SNOWBALLS and SPRITZ disputes demonstrate, words that seem like natural choices for a product can still attract challenges from businesses that hold trade mark rights in those terms. This is why product names should be included in trade mark clearance processes alongside core brand names before products go to market.

With Christmas approaching, a disagreement over a chocolate product name has attracted attention well beyond the confectionery aisle.  Cadbury’s owner, Mondelēz International, has reportedly asked British dairy-free chocolate maker Moo Free to stop selling its “White Choccy Snowballs”, alleging infringement of its registered trade marks SNOWBALL and SNOWBALLS.

Closer to home, Bickford’s and Noot Drinks are in a dispute over SPRITZ.  Bickford’s holds an Australian registration for SPRITZ for non-alcoholic soft drinks, and has brought Federal Court proceedings alleging infringement in relation to Noot’s use of “Negroni Spritz” and “Limoncello Spritz”.

Different disputes at different stages

Mondelēz has said that no legal proceedings have been commenced and that it is open to an amicable resolution.  Moo Free disputes that infringement has been established.

The SPRITZ dispute, meanwhile, has progressed to litigation.  Noot’s position includes an argument that “Spritz” is not being used as a trade mark, but rather is being used descriptively.  The published decisions address procedural and evidentiary matters, and no final determination has been made on the infringement claim.

Although the disputes arise in different markets and legal settings, both offer a useful perspective on the commercial tensions surrounding familiar product names.

When familiar language meets existing rights

What happens if a product name infringes a trade mark?

A rights holder may send a cease-and-desist letter, request that use of the name stop, negotiate a resolution or commence legal proceedings. Even where litigation does not occur, businesses may incur significant costs through rebranding, packaging changes and product recalls. The SNOWBALLS and SPRITZ disputes demonstrate that even product names based on familiar words can lead to enforcement action, creating disruption and expense long before any court reaches a final decision.

Both disputes involve an established rights holder objecting to another business’s use of a familiar word in a product name.  They highlight the tension that can arise when language that feels like a natural choice for a product also forms part of another trader’s brand portfolio.

When developing a new range, businesses understandably devote considerable attention to the main brand.  Individual product names may receive less scrutiny, particularly where they draw on familiar seasonal language, flavours or shapes.  Yet those names can carry substantial investment of their own.

The practical lesson is to consider product names as part of the trade mark clearance process before committing to packaging, promotional material and retailer listings.  A name’s familiarity should prompt an assessment of its availability, rather than an assumption that it is free to use.

Timing matters.  Identifying a potential conflict while a name is still under development gives a business greater flexibility to respond.  Once stock has been produced and launch commitments made, even a dispute that never reaches court can cause significant commercial disruption.

Protecting the brand beyond the legal claim

Enforcement also has a communication dimension.  Brand owners invest in building recognition and have a commercial interest in protecting it.  For a business receiving a demand, the immediate concern may be the cost and disruption of changing a product name.

When a dispute becomes public, customers often encounter these competing perspectives through headlines and social media, without access to the underlying correspondence or the full circumstances.  The tone, timing and scope of an enforcement approach can therefore influence perceptions of the brand itself.

A consideration before the next launch

Should businesses check product names as well as brand names?

Yes. Many businesses carefully clear their company and master brand names but devote less attention to individual product names. The same trade mark risks can arise in relation to product names, flavours, seasonal ranges and limited-edition releases. As the recent SNOWBALLS and SPRITZ disputes demonstrate, a product name can become the focal point of a trade mark conflict, even where the underlying brand itself is not in dispute.

SNOWBALLS and SPRITZ offer a shared reminder that product naming deserves attention early in the development process.

For businesses launching products, that means assessing availability before investment and commitments accumulate.

For rights holders, it means considering how enforcement supports the brand’s broader commercial interests.

A familiar name may seem an intuitive choice.  Establishing whether it is available is an essential step before making it part of the brand.

The key takeaway

Businesses are often surprised to discover that words chosen because they seem familiar, descriptive or intuitive may already form part of another trader’s registered trade mark portfolio.  By the time a conflict is identified, significant investment may already have been made in packaging, marketing materials, retailer listings and launch activities.

Taking a strategic approach to trade mark clearance can help reduce these risks.  At Pearce IP, we regularly assist clients with trade mark availability assessments, clearance searches and brand protection strategies covering not only company and house brands, but also individual product names, sub-brands, line extensions and future product ranges.  Identifying potential issues early in the development process provides greater flexibility and can help avoid costly rebranding exercises, launch delays and trade mark disputes further down the track.

Contact Pearce IP for assistance with clearance, protection and management of a new product or brand in Australia, New Zealand or internationally. Use our Contact Form or email us at info@pearceIP.law or call Australia Tel: +61 (0) 2 9023 9988 or New Zealand Tel: +64 (4) 886 1199.

While this article provides an overview of the issues discussed, it does not constitute legal advice. If the topic affects your business or personal circumstances, we recommend seeking advice specific to your situation.


 

About Pearce IP

Pearce IP is a privately owned/independent, specialist, life-sciences focussed, intellectual property/law firm offering lawyers and attorneys in Australia and New Zealand.

Our lawyers and attorneys specialise in pharma, biopharma, biotech, ag-tech, food-tech, med-tech, although our work is broader than these industries.

Pearce IP and its leaders are ranked in every notable legal directory including: Chambers & Partners, Legal 500, IAM Patent 1000, IAM Strategy 300, MIP IP Stars, Doyles Guide, WTR 1000, Best Lawyers, WIPR Leaders, Best Law Firms, among others. In 2025, Pearce IP was honoured by Australasian Lawyer and New Zealand Lawyer as a Top Specialist Firm, 5 Star Employer of Choice, and the “Standout Winner” for Inclusion and Culture (<100 employees).  

Pearce IP is the only leading IP firm in Australia and New Zealand with a female founder, and is certified by WEConnect International as women owned.

 

Sally Paterson

Sally Paterson

Executive, Lawyer (NZ), Patent & Trade Mark Attorney (AU, NZ)

Sally is a senior Trans-Tasman Patent and Trade Mark Attorney, and a New Zealand registered lawyer with over 20 years’ experience in IP.  Sally’s particular expertise is in life sciences, drawing from her background in biological sciences. Sally is well respected in the New Zealand IP community for her broad ranging skills in all aspects of intellectual property advice, protection and enforcement. Sally has extensive experience securing registration for patents, designs and trade marks in New Zealand, Australia and internationally, providing strategic infringement, validity and enforceability opinions, acting in contentious disputes including matters before the courts of New Zealand and before IPONZ and IP Australia, and advising on copyright and consumer law matters.

Naomi Pearce

Naomi Pearce

CEO, Executive Lawyer (AU, NZ), Patent & Trade Mark Attorney (Trans Tasman)

Naomi is the CEO and Founder of Pearce IP, and is one of ANZ’s leading IP practitioners. Naomi is a market leading, strategic, commercially astute, patent lawyer, patent attorney and trade mark attorney, with over 29 years’ experience, and a background in molecular biology/biochemistry.

Ranked in virtually every notable legal directory, highly regarded by peers and clients, Naomi is renowned for her successful and elegant IP/legal strategies focussing on complex/multijurisdictional litigation, global FTO, and strategic advice.  Among other awards, Naomi is the 2026 Lexology Client Choice Winner for Patents, the 2024 Lawyers Weekly Women in Law “Executive of the Year”, the 2023 Lawyers Weekly “IP Partner of the Year”, the 2022 Lexology Client Choice Winner for Life Sciences, the 2022 Asia Pacific Women in Business Law “Patent Lawyer of the Year”, and the 2021 Lawyers Weekly Women in Law “Partner of the Year”.  Ranked in Chambers Asia Pacific, Chambers Global,  IAM Patent 1000, IAM Strategy 300, is a MIP “Patent Star”, and is recognised as a WIPR Leader for patents and trade marks.

Pearce IP is the premier life sciences focussed firm in ANZ.  Commencing in 2017. Pearce IP is the 2025 Australasian Lawyer and NZ Lawyer 5-Star Employer of Choice & “Standout Winner” for Inclusion and Culture (<100 employees).  In 2021, Pearce IP was the Lawyers Weekly Australian Law Awards IP Team of the Year.

Pearce IP BioBlast® for the week ending 6 November 2026

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®.  Significant biosimilar activities for the week ending 6 November 2026 are set out below:


Aflibercept

On 2 November 2026, South Korea’s The Financial News, reported that Sam Chun Dang (SCD) has entered into an exclusive sales and supply agreement in Japan with… Read more here.

Denosumab, Ustekinumab

On 5 November 2026, Celltrion announced that it launched three biosimilars in Brazil in October 2026: Qoyvolma®, biosimilar to Janssen’s Stelara® (ustekinumab), and… Read more here.

Etanercept, Infliximab

On 3 November 2026, Samsung Bioepis and Teva announced they have entered a licence and commercialisation agreement for Eticovo®, biosimilar to Immunex/Amgen’s… Read more here.

Golimumab

On 6 November 2026, Bio-Thera Solutions announced that China’s National Medical Products Administration (NMPA) has approved BAT2506, biosimilar to Janssen’s… Read more here.

Semaglutide

On 9 November 2026, Sandoz announced that it has launched Owozy™, a generic version of Novo Nordisk’s Ozempic® (semaglutide), in Brazil.  This is the first… Read more here.

Biopharma Deals

On 2 November 2026, Fresenius announced that it has entered an exclusive development agreement with WuXi Biologics, a large-scale biologics developer and… Read more here.

About Pearce IP

Pearce IP is a privately owned/independent, specialist, life-sciences focussed, intellectual property/law firm offering lawyers and attorneys in Australia and New Zealand.

Our lawyers and attorneys specialise in pharma, biopharma, biotech, ag-tech, food-tech, med-tech, although our work is broader than these industries.

Pearce IP and its leaders are ranked in every notable legal directory including: Chambers & Partners, Legal 500, IAM Patent 1000, IAM Strategy 300, MIP IP Stars, Doyles Guide, WTR 1000, Best Lawyers, WIPR Leaders, Best Law Firms, among others. In 2025, Pearce IP was honoured by Australasian Lawyer and New Zealand Lawyer as a Top Specialist Firm, 5 Star Employer of Choice, and the “Standout Winner” for Inclusion and Culture (<100 employees).  

Pearce IP is the only leading IP firm in Australia and New Zealand with a female founder, and is certified by WEConnect International as women owned.

 

Naomi Pearce

Naomi Pearce

CEO, Executive Lawyer (AU, NZ), Patent & Trade Mark Attorney (Trans Tasman)

Naomi is the CEO and Founder of Pearce IP, and is one of ANZ’s leading IP practitioners. Naomi is a market leading, strategic, commercially astute, patent lawyer, patent attorney and trade mark attorney, with over 29 years’ experience, and a background in molecular biology/biochemistry.

Ranked in virtually every notable legal directory, highly regarded by peers and clients, Naomi is renowned for her successful and elegant IP/legal strategies focussing on complex/multijurisdictional litigation, global FTO, and strategic advice.  Among other awards, Naomi is the 2026 Lexology Client Choice Winner for Patents, the 2024 Lawyers Weekly Women in Law “Executive of the Year”, the 2023 Lawyers Weekly “IP Partner of the Year”, the 2022 Lexology Client Choice Winner for Life Sciences, the 2022 Asia Pacific Women in Business Law “Patent Lawyer of the Year”, and the 2021 Lawyers Weekly Women in Law “Partner of the Year”.  Ranked in Chambers Asia Pacific, Chambers Global,  IAM Patent 1000, IAM Strategy 300, is a MIP “Patent Star”, and is recognised as a WIPR Leader for patents and trade marks.

Pearce IP is the premier life sciences focussed firm in ANZ.  Commencing in 2017. Pearce IP is the 2025 Australasian Lawyer and NZ Lawyer 5-Star Employer of Choice & “Standout Winner” for Inclusion and Culture (<100 employees).  In 2021, Pearce IP was the Lawyers Weekly Australian Law Awards IP Team of the Year.

Chantal Savage

Chantal Savage

Special Counsel, Lawyer

Chantal is an intellectual property disputes lawyer with experience advising across the spectrum of IP rights, including patents, trade marks, copyright, plant breeder’s rights and trade secrets/confidential information. Recognised as a Rising Star in IP by the Legal 500 Asia Pacific (2021-2024), Chantal has previously worked for international and top tier law firms in Australia and the United Kingdom.

With a science degree specialising in molecular biology and biochemistry, Chantal’s practice focuses particularly on complex, high-value, multi-jurisdictional patent infringement and revocation proceedings for clients in the life sciences sectors.

Sandoz Launches Generic Ozempic® (Semaglutide) in Brazil

On 9 November 2026, Sandoz announced that it has launched Owozy™, a generic version of Novo Nordisk’s Ozempic® (semaglutide), in Brazil.  This is the first semaglutide launch for Sandoz worldwide.

Owozy™ was developed by Malta-headquartered Adalvo and was approved in Brazil on 29 July 2026 for the treatment of type 2 diabetes.  According to Sandoz, Owozy™ is among the earliest new semaglutide treatment options available in Brazil, which has a GLP-1 market estimated to be worth USD 2.7 billion, with more than 16.5 million Brazilians living with diabetes.

The launch of Owozy™ in Brazil follows the approval of Sandoz’s generic semaglutide in Canada in September 2026, which is expected to launch by the end of 2026.

A number of generic semaglutide products have now been launched around the world.  In March 2026, Dr Reddy’s, Zydus, Alkem, Sun Pharma and Glenmark launched generic semaglutide products on the Indian market, following the expiry of Novo Nordisk’s core Indian patent for semaglutide.  Generic semaglutide products were also launched in Canada in May 2026 by Apotex and Dr Reddy’s.  Sun Pharma’s generic semaglutide injection was approved in South Africa (announced 15 July 2026), with launch following shortly thereafter.

Apotex received the first US FDA Tentative Approval for its generic semaglutide ANDA in April 2026, giving it an opportunity to be one of the first to launch generic Ozempic® in the US following expiry of Novo Nordisk’s exclusivity/patents.  Novo Nordisk has sued Apotex in the US in relation to generic Rybelsus®, Ozempic® and Wegovy®, alleging patent infringement, with the three cases being consolidated in June 2026.  Novo Nordisk also commenced Hatch Waxman litigation against Cipla in July 2026 in relation to generic semaglutide products.

Bio-Thera Secures First Approved Biosimilar Golimumab in China

On 6 November 2026, Bio-Thera Solutions announced that China’s National Medical Products Administration (NMPA) has approved BAT2506, biosimilar to Janssen’s Simponi® (golimumab), which will be marketed under the name 阿舒立® (Ashuli).  This is the first golimumab biosimilar to be approved in China.

BAT2506 was also the first (and to date remains the only) biosimilar golimumab approved in the US (in May 2026), where it will be commercialised by Accord BioPharma under the names Immgolis™ (referencing Simponi®) and Immgolis Intri™ (referencing Simponi® Aria).  On 30 September 2026, the US District Court for the District of Delaware granted Janssen a preliminary injunction preventing Accord/Bio-Thera from launching Immgolis™ and Immgolis Intri™ in the US during the term of the relevant patent(s).  The preliminary injunction was granted in the context of BPCIA proceedings commenced by Janssen against Accord and Bio-Thera on 3 March 2026, alleging that Immgolis™ and Immgolis Intri™ infringe 17 Janssen patents.  Accord and Bio-Thera have appealed the injunction decision (which is not yet publicly available), with a Notice of Appeal filed on 1 October 2026.

BAT2506 was approved in Europe, under the name Gotenfia®, in February 2026.  Gotenfia® is being commercialised in Europe by STADA under a May 2024 agreement.  It was the second golimumab biosimilar to be approved in Europe, following the approval of Alvotech/Advanz’s Gobivaz® (AVT05) in November 2025.

Bio-Thera has entered commercialisation agreements for BAT2506, including with Intas for Latin America (announced March 2026) and Canada ( announced October 2025), SteinCares for Latin America (announced March 2024) and Dr Reddy’s for South East Asia (announced March 2025).

Celltrion Launches Ustekinumab & Denosumab Biosimilars in Brazil

On 5 November 2026, Celltrion announced that it launched three biosimilars in Brazil in October 2026: Qoyvolma®, biosimilar to Janssen’s Stelara® (ustekinumab), and Stoboclo® and Osenvelt®, biosimilars to Amgen’s Prolia® and Xgeva® (denosumab), respectively.

Qoyvolma® is approved for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.  Stoboclo® and Osenvelt® are approved for the same indications as the reference medicine.

With this launch, Celltrion’s product range in Brazil has expanded to a total of 10 products, including infliximab, adalimumab, and omalizumab biosimilars.  Celltrion is planning to launch Eydenzelt®, biosimilar to Regeneron/Bayer’s Eylea® (aflibercept) and Avtozma®, biosimilar to Roche’s Actemra® (tocilizumab), in Brazil before the end of the year.

The launch of Celltrion’s ustekinumab biosimilar follows news that Biocon’s Yesintek® (ustekinumab) was permitted to enter the Brazilian market “with immediate effect” following a settlement agreement entered into by Biocon and Janssen in October 2026.  Bio-Thera and Biomm entered a licensing agreement for Bio-Thera’s BAT2206 (ustekinumab) in Brazil in June 2023.

There have been at least two reported denosumab biosimilar approvals in Brazil to date.  Sandoz’s Denbonli® (referencing Amgen’s Prolia®) and Wyost® (referencing Amgen’s Xgeva®) received approval in September 2025.  Abbott/mAbxience received approval for two unnamed denosumab biosimilars in June 2026.  There are denosumab biosimilars under development for the Brazilian market by at least Mabwell/Cristália (strategic agreement entered August 2024) and Boan Biotech and an unnamed strategic partner (strategic agreement entered November 2024).

Pearce IP BioBlast® for the week ending 30 October 2026

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®.  Significant biosimilar activities for the week ending 30 October 2026 are set out below:


Denosumab

On 30 October 2026, China-headquartered Boan Biotech announced that it has licensed BA6101 (denosumab), biosimilar to Amgen’s Prolia® (marketed in Japan as… Read more here.

Omalizumab, Tocilizumab

On 26 October 2026, Celltrion announced that its US subsidiary has signed an exclusive supply agreement with a major US healthcare company for its pre-filled syringe… Read more here.

Pembrolizumab

On 30 October 2026, Samsung Bioepis announced that it has applied to the FDA for marketing authorisation of SB27, biosimilar to MSD’s Keytruda® (pembrolizumab)… Read more here.

Ranibizumab

On 27 October 2026, STADA and Xbrane Biopharma (Xbrane) announced that the FDA has approved Lucamzi™ (ranibizumab-blrz), biosimilar to Genentech’s Lucentis®… Read more here.

Secukinumab

On 26 October 2026, Bio-Thera Solutions announced that it has received marketing authorisation from China’s National Medical Products Administration (NMPA) for… Read more here.

Ustekinumab

On 26 October 2026, Biocon announced that it has signed a licence agreement with Janssen clearing the way for the commercialization of Yesintek™, biosimilar to… Read more here.

About Pearce IP

Pearce IP is a privately owned/independent, specialist, life-sciences focussed, intellectual property/law firm offering lawyers and attorneys in Australia and New Zealand.

Our lawyers and attorneys specialise in pharma, biopharma, biotech, ag-tech, food-tech, med-tech, although our work is broader than these industries.

Pearce IP and its leaders are ranked in every notable legal directory including: Chambers & Partners, Legal 500, IAM Patent 1000, IAM Strategy 300, MIP IP Stars, Doyles Guide, WTR 1000, Best Lawyers, WIPR Leaders, Best Law Firms, among others. In 2025, Pearce IP was honoured by Australasian Lawyer and New Zealand Lawyer as a Top Specialist Firm, 5 Star Employer of Choice, and the “Standout Winner” for Inclusion and Culture (<100 employees).  

Pearce IP is the only leading IP firm in Australia and New Zealand with a female founder, and is certified by WEConnect International as women owned.

 

Naomi Pearce

Naomi Pearce

CEO, Executive Lawyer (AU, NZ), Patent & Trade Mark Attorney (Trans Tasman)

Naomi is the CEO and Founder of Pearce IP, and is one of ANZ’s leading IP practitioners. Naomi is a market leading, strategic, commercially astute, patent lawyer, patent attorney and trade mark attorney, with over 29 years’ experience, and a background in molecular biology/biochemistry.

Ranked in virtually every notable legal directory, highly regarded by peers and clients, Naomi is renowned for her successful and elegant IP/legal strategies focussing on complex/multijurisdictional litigation, global FTO, and strategic advice.  Among other awards, Naomi is the 2026 Lexology Client Choice Winner for Patents, the 2024 Lawyers Weekly Women in Law “Executive of the Year”, the 2023 Lawyers Weekly “IP Partner of the Year”, the 2022 Lexology Client Choice Winner for Life Sciences, the 2022 Asia Pacific Women in Business Law “Patent Lawyer of the Year”, and the 2021 Lawyers Weekly Women in Law “Partner of the Year”.  Ranked in Chambers Asia Pacific, Chambers Global,  IAM Patent 1000, IAM Strategy 300, is a MIP “Patent Star”, and is recognised as a WIPR Leader for patents and trade marks.

Pearce IP is the premier life sciences focussed firm in ANZ.  Commencing in 2017. Pearce IP is the 2025 Australasian Lawyer and NZ Lawyer 5-Star Employer of Choice & “Standout Winner” for Inclusion and Culture (<100 employees).  In 2021, Pearce IP was the Lawyers Weekly Australian Law Awards IP Team of the Year.

Chantal Savage

Chantal Savage

Special Counsel, Lawyer

Chantal is an intellectual property disputes lawyer with experience advising across the spectrum of IP rights, including patents, trade marks, copyright, plant breeder’s rights and trade secrets/confidential information. Recognised as a Rising Star in IP by the Legal 500 Asia Pacific (2021-2024), Chantal has previously worked for international and top tier law firms in Australia and the United Kingdom.

With a science degree specialising in molecular biology and biochemistry, Chantal’s practice focuses particularly on complex, high-value, multi-jurisdictional patent infringement and revocation proceedings for clients in the life sciences sectors.

Samsung Bioepis & Teva Enter US$420m Commercialisation Deal for Etanercept and Infliximab Biosimilars in US

On 3 November 2026, Samsung Bioepis and Teva announced they have entered a licence and commercialisation agreement for Eticovo®, biosimilar to Immunex/Amgen’s Enbrel® (etanercept), and Renflexis®, biosimilar to Janssen’s Remicade® (infliximab).  According to a regulatory filing by Samsung Bioepis, the deal is worth up to 563.2 billion won (US$420 million).

Under the terms of the agreement, Teva will obtain US commercialisation rights to Eticovo® at closing (anticipated by the end of 2026), while the US commercialisation rights to biosimilar infliximab will transfer to Teva in Q3/2027.  Samsung Bioepis will remain responsible for regulatory oversight and manufacturing of both products.

Subject to certain conditions, Teva will pay Samsung Bioepis an upfront payment over the next 3 years.  Samsung Bioepis may also be eligible for additional launch and sales milestone payments.  Teva and Samsung Bioepis will share the profits from the commercialisation of the biosimilars.

Samsung Bioepis’ Eticovo® was approved by the FDA in April 2019.  Samsung Bioepis is prevented from launching Eticovo® in the US until 2029 by a permanent injunction granted by the US District Court for the District of New Jersey in November 2021.  Samsung Bioepis’ Renflexis® (infliximab-abda) was approved in the US in April 2017.

Teva and Samsung Bioepis first entered into a strategic partnership in January 2025 for the US-commercialisation of Samsung Bioepis’ Epysqli® (eculizumab-aagh), biosimilar to Alexion’s Soliris®.  In July 2026, that agreement was expanded to include the commercialisation of Samsung Bioepis’ Opuviz® (aflibercept), biosimilar to Regeneron/Bayer’s Eylea®, in Canada.

On 1 October 2026, Samsung Bioepis and Teva announced a global collaboration and licence agreement for the US, Canada and Europe, to expand their existing partnership for up to six additional biosimilars, including SB44, biosimilar to Novartis’ Ilaris® (canakinumab), and SB41, biosimilar to AstraZeneca’s Fasenra® (benralizumab), plus four other undisclosed early-stage biosimilars.

Why New Zealand Agriculture’s Global Success Makes Intellectual Property Protection Essential

Have your say: help shape our free IP in Agriculture Masterclass

Pearce IP’s life science and bioscience experts are preparing a free, live Masterclass exploring the IP issues shaping the future of agriculture and animal health.


Explore the issues below and vote for the topic you would most like us to cover — or send us your own questions and challenges.

VOTE NOW >

New Zealand may be small in population, but its agricultural reach is anything but. For businesses producing, developing or commercialising the products and technologies behind global food production, protecting agricultural intellectual property is an increasingly important part of protecting commercial value.

 

A small country with a big role in feeding the world

With a population of around 5.3 million, New Zealand might seem an unlikely agricultural powerhouse. Yet its influence on global food production and trade extends far beyond its size, making the protection of the intellectual property behind its agricultural success increasingly important.

In the year to 30 June 2026, New Zealand’s food and fibre exports reached a record NZ$65.2 billion[1], an increase of 8% on the previous year.  Dairy exports alone generated NZ$28.8 billion.  These figures reflect an industry that is not simply producing food for domestic consumption, but supplying valuable products to markets around the world.

In the latest year, New Zealand was the world’s largest exporter of Concentrated Milk ($6.19B), Butter ($2.92B), Rough Wood ($1.84B), Casein ($860M), and Honey ($250M) among three other products.[2]

From milk, butter and meat to wine, honey and horticultural products, New Zealand has built an international reputation for agricultural production and export capability.  Its farmers, growers, processors, researchers and agribusinesses operate within a global supply chain in which quality, productivity, reliability and commercial relationships matter.

And the story extends well beyond what leaves the farm gate.

 

The commercial opportunity extends around the world

Agriculture is a global business.  Demand for food, animal products and beverages continues throughout the year, while growing conditions, harvests and supply cycles vary between regions.

New Zealand’s Southern Hemisphere location creates opportunities to serve international markets with different production seasons.  Alongside Australia, it occupies a strategically valuable position in the global agricultural landscape, supplying products to customers whose domestic production cycles and seasonal availability may differ.

Its established export relationships are another important part of the picture. China, with its enormous population and demand for food products, is a particularly significant trading partner.  New Zealand’s broader network of international markets also creates opportunities for businesses that can develop products, technologies and services suited to different agricultural systems and consumer needs.

Agricultural intellectual property - New Zealand Top Global Exports holding the largest share of the product market

Reference oec.world/en/profile/country/nzl

New Zealand’s distinctive commercial ecosystem

Trade is only one part of the advantage. New Zealand’s agricultural sector has developed a distinctive commercial ecosystem, bringing together farmer-owned cooperatives, specialist producers, research organisations, technology developers and internationally active businesses.

Examples include:

  • Fonterra: Dairy production, processing and international exports.
  • Zespri: Grower-owned kiwifruit marketing and global distribution.
  • Silver Fern Farms: Farmer-owned red meat processing and exports.
  • Livestock Improvement Corporation (LIC): Dairy genetics, herd improvement and agricultural technology.
  • Ravensdown: Fertiliser, nutrient management and agricultural services.
  • Ballance Agri-Nutrients: Fertiliser and nutrient management solutions.
  • Tatua Co-operative Dairy Company: Specialised dairy ingredients and products.
  • Dairy Goat Co-operative: Goat milk products and specialised dairy nutrition.

Together, these businesses demonstrate how New Zealand’s agricultural sector can combine producer expertise, shared resources, specialist technology and international market access to compete globally.  They also highlight the importance of getting intellectual property right.  Whether businesses are collaborating on research, developing new plant varieties or animal genetics, sharing technology or commercialising products, clear agreements on IP ownership, protection and commercialisation are essential to safeguarding the value created through these partnerships.

 

The IP value behind the product

When we think about agricultural exports, it is easy to focus on the finished product: the milk, the meat, the honey or the wine.  But the commercial value of modern agriculture often begins long before a product reaches the market.

Behind a successful agricultural product may be years of research, breeding, experimentation, investment and specialist knowledge.  A new plant variety may offer improved yield, flavour, shelf life or disease resistance.  A biotechnology development may improve crop protection or animal health.  A new piece of agricultural technology may help producers monitor conditions, improve productivity or use resources more efficiently.

Then there are the brands that distinguish products in competitive international markets, the data that informs decisions, and the confidential know-how that gives a business an advantage over its competitors.

These assets can be just as commercially significant as the physical products themselves.

New Zealand’s plant breeding sector provides a tangible example.  Plant variety rights can give breeders exclusive rights to commercialise qualifying new varieties, helping them recoup the investment involved in developing plants with desirable characteristics.  The New Zealand Government identifies plant variety rights as an important mechanism for encouraging investment in breeding and supporting export value.

The principle extends across the agricultural sector: the more value a business creates through research, development, technology and distinctive products, the more important it becomes to understand how that value can be protected and commercialised.

 

Why intellectual property matters in New Zealand agriculture

For businesses operating in New Zealand agriculture — or considering entering the market — intellectual property should be part of the commercial strategy from the outset.

The right approach will depend on the asset, the business model and the markets involved. Patents, plant variety rights, trade marks, contractual arrangements and protection of confidential information each serve different purposes. An effective IP strategy considers how these protections work together.

Consider some of the questions that can arise:

  • Plant varieties and breeding: Who owns a newly developed variety, and what protection is available in New Zealand and overseas?
  • Patents and biotechnology: Could a new invention, process or technology qualify for patent protection, and where should protection be sought?
  • Brands and trade marks: Is the name or logo that distinguishes an agricultural product protected in the markets where it will be sold?
  • Research and collaboration: Who owns the resulting IP when a business works with a university, research organisation, grower, supplier or commercial partner?
  • Data and confidential information: Who can access, use and commercialise valuable agricultural data, technical information and know-how?
  • Licensing and market entry: What rights does a business need to commercialise technology, distribute products or collaborate with partners in New Zealand?

These are not simply legal questions. They can affect investment decisions, commercial negotiations, market access, licensing opportunities and the ability to expand internationally.

 

Protecting the value of New Zealand agriculture

New Zealand’s agricultural success has been built on more than favourable growing conditions and access to international markets.  It also reflects the expertise of its farmers and growers, the strength of its commercial relationships, and continued investment in products, processes and technologies.

With food and fibre exports reaching record levels, the commercial stakes are substantial. The opportunity is not limited to established producers: it extends to agricultural technology developers, biotechnology businesses, researchers, investors, brand owners and international companies seeking to participate in New Zealand’s agricultural economy.

For these businesses, IP is not simply something to address when a dispute arises or a product is ready to launch. It is a consideration throughout the development and commercialisation process — from early research and collaboration through to branding, licensing and international expansion.

Understanding what you own, what you need to protect, and how you intend to commercialise it can make a meaningful difference to the value your business is able to create and retain.

 

Help shape the discussion

Pearce IP’s life sciences and biosciences experts are preparing a free, live IP in Agriculture Masterclass for businesses operating in Australia and New Zealand.

Which topic matters most to your business? Vote for your preferred topic or send us your questions and suggestions to help shape the Masterclass to info@pearceip.law.

 

[1] Source: Published 9 October 2026 New Zealand’s food and fibre exports reached NZ$65.2 billion in the year to June 2026 Back to text ↑

[2] Source: Historical Data 2022-2024 in USD New Zealand was the world’s largest exporter of Concentrated Milk, Butter ($2.89B), Rough Wood ($1.85B), Casein ($853M), and Honey Back to text ↑


 

About Pearce IP

Pearce IP is a privately owned/independent, specialist, life-sciences focussed, intellectual property/law firm offering lawyers and attorneys in Australia and New Zealand.

Our lawyers and attorneys specialise in pharma, biopharma, biotech, ag-tech, food-tech, med-tech, although our work is broader than these industries.

Pearce IP and its leaders are ranked in every notable legal directory including: Chambers & Partners, Legal 500, IAM Patent 1000, IAM Strategy 300, MIP IP Stars, Doyles Guide, WTR 1000, Best Lawyers, WIPR Leaders, Best Law Firms, among others. In 2025, Pearce IP was honoured by Australasian Lawyer and New Zealand Lawyer as a Top Specialist Firm, 5 Star Employer of Choice, and the “Standout Winner” for Inclusion and Culture (<100 employees).  

Pearce IP is the only leading IP firm in Australia and New Zealand with a female founder, and is certified by WEConnect International as women owned.

 

Paul Johns

Paul Johns

Executive, Lawyer (Head of Litigation – New Zealand)

Paul is an intellectual property dispute resolution specialist with more than 24 years of experience across New Zealand and the UK. Paul is a seasoned lawyer, IP strategist, and Head of Pearce IP’s litigation team in New Zealand.  Paul appears in cases before the New Zealand Court of Appeal and High Court of New Zealand, as well as the New Zealand Intellectual Property Office and IP Australia

Paul is experienced in managing contentious disputes regarding all types of intellectual property and related issues, including patents, copyright, trade marks, designs, confidential information and consumer law. With a background in molecular genetics, Paul has acted for clients across a vast range of industries, including pharmaceuticals, biotechnology, animal health, med-tech, food & beverage technologies, heavy vehicle engineering, fashion, hospitality, and entertainment. Paul is recommended for litigation in the IAM Patent 1000, rated for enforcement and litigation in the WTR1000, ranked for Intellectual Property Asia-Pacific in Chambers, and recognised for Intellectual Property and Litigation in Best Lawyers.

Naomi Pearce

Naomi Pearce

CEO, Executive Lawyer (AU, NZ), Patent & Trade Mark Attorney (Trans Tasman)

Naomi is the CEO and Founder of Pearce IP, and is one of ANZ’s leading IP practitioners. Naomi is a market leading, strategic, commercially astute, patent lawyer, patent attorney and trade mark attorney, with over 29 years’ experience, and a background in molecular biology/biochemistry.

Ranked in virtually every notable legal directory, highly regarded by peers and clients, Naomi is renowned for her successful and elegant IP/legal strategies focussing on complex/multijurisdictional litigation, global FTO, and strategic advice.  Among other awards, Naomi is the 2026 Lexology Client Choice Winner for Patents, the 2024 Lawyers Weekly Women in Law “Executive of the Year”, the 2023 Lawyers Weekly “IP Partner of the Year”, the 2022 Lexology Client Choice Winner for Life Sciences, the 2022 Asia Pacific Women in Business Law “Patent Lawyer of the Year”, and the 2021 Lawyers Weekly Women in Law “Partner of the Year”.  Ranked in Chambers Asia Pacific, Chambers Global,  IAM Patent 1000, IAM Strategy 300, is a MIP “Patent Star”, and is recognised as a WIPR Leader for patents and trade marks.

Pearce IP is the premier life sciences focussed firm in ANZ.  Commencing in 2017. Pearce IP is the 2025 Australasian Lawyer and NZ Lawyer 5-Star Employer of Choice & “Standout Winner” for Inclusion and Culture (<100 employees).  In 2021, Pearce IP was the Lawyers Weekly Australian Law Awards IP Team of the Year.

Sally Paterson

Sally Paterson

Executive, Lawyer (NZ), Patent & Trade Mark Attorney (AU, NZ)

Sally is a senior Trans-Tasman Patent and Trade Mark Attorney, and a New Zealand registered lawyer with over 20 years’ experience in IP.  Sally’s particular expertise is in life sciences, drawing from her background in biological sciences. Sally is well respected in the New Zealand IP community for her broad ranging skills in all aspects of intellectual property advice, protection and enforcement. Sally has extensive experience securing registration for patents, designs and trade marks in New Zealand, Australia and internationally, providing strategic infringement, validity and enforceability opinions, acting in contentious disputes including matters before the courts of New Zealand and before IPONZ and IP Australia, and advising on copyright and consumer law matters.

Fresenius and WuXi Enter Exclusive Development Agreement for up to 37 Biosimilars

On 2 November 2026, Fresenius announced that it has entered an exclusive development agreement with WuXi Biologics, a large-scale biologics developer and manufacturer of monoclonal and bispecific antibodies and antibody-drug conjugates.  According to Fresenius, this is the largest development agreement announced in the biosimilars industry to date.

The agreement provides Fresenius with exclusive access to up to 37 identified biosimilar candidates over the next decade.  If Fresenius exercises all of its options, its portfolio of marketed and pipeline molecules would grow from 29 to as many as 66.

The products developed under the agreement are expected to span 13 therapeutic areas, including neurology, nephrology, cardiopulmonary, oncology, immunology, and gastroenterology, and will include monoclonal and bispecific antibodies, antibody-drug conjugates and fusion proteins.  Initial development is expected to focus on polatuzumab vedotin, biosimilar to Genentech’s Polivy®, an antibody-drug conjugate for the treatment of diffuse large B-cell lymphoma, and teprotumumab, biosimilar to Amgen’s Tepezza®, a monoclonal antibody for the treatment of Thyroid Eye Disease.

Under the terms of the agreement, WuXi will be paid on a fee-for-service basis for each candidate Fresenius selects for development.  Fresenius retains exclusive global commercialisation rights, including marketing authorisations, and the full economics of any commercialised products.

The agreement builds on Fresenius’ full acquisition of mAbxience, completion of which was announced on 1 October 2026.

Sam Chun Dang Partners with Daiichi Sankyo Subsidiary for Commercialisation of Biosimilar Aflibercept in Japan

On 2 November 2026, South Korea’s The Financial News, reported that Sam Chun Dang (SCD) has entered into an exclusive sales and supply agreement in Japan with Daiichi Sankyo Espha (DSE) for SCD411, biosimilar to Regeneron/Bayer’s Eylea (aflibercept), 2 mg.  In doing so, SCD has terminated an agreement with Senju Pharmaceutical, its existing partner for the aflibercept biosimilar in Japan.

Under the new agreement with DSE, SCD now holds the marketing authorisation in its own name through Japan’s special approval system for foreign manufacturers.  This is a change from the previous arrangement in which Senju Pharmaceutical held the marketing authorisation.  DSE has responsibility under the agreement for local sales and promotion of SCD411 2 mg pre-filled syringes and vials.

In August 2026, SCD signed a settlement agreement with Regeneron and Bayer to resolve all patent disputes in Europe, Korea and Japan involving SCD411.  The financial terms of the settlement have not been disclosed.

SCD411 was approved in vial and pre-filled syringe forms in Japan and Korea in September 2025.  It has not yet been launched in Japan but was launched in Korea as Vgenfli™ in December 2025.

In Europe, SCD411 was approved as Vgenfli™ in August 2025, with Zaklady Farmaceutyczne Polpharma as the marketing authorisation holder.  SCD has announced licence agreements with an unnamed distributor for Austria, Germany, Italy, Spain and Switzerland (November 2023), and a further unnamed distributor for the UK, Belgium, Netherlands, Norway, Portugal, Sweden, Greece, Ireland and Finland (March 2024).

SCD and its US exclusive licensee, Fresenius Kabi, settled US aflibercept litigation with Regeneron/Bayer in February 2026.  The settlement permits Fresenius to launch SCD411/Vygenfree™ in the US at an undisclosed time.  The FDA accepted SCD’s application for SCD411 for review in December 2025 but the biosimilar has not yet been FDA-approved.

Regeneron, Bayer and Apotex, SCD’s commercialisation partner under an August 2023 agreement, settled their Canadian aflibercept litigation in June 2024.  Health Canada approved SCD411 as Aflivu™ in June 2025 and it was launched in July 2025.

Samsung Bioepis Files US Application for Biosimilar to MSD’s Keytruda® (Pembrolizumab)

On 30 October 2026, Samsung Bioepis announced that it has applied to the FDA for marketing authorisation of SB27, biosimilar to MSD’s Keytruda® (pembrolizumab), across 18 cancer indications.

This is the second reported US filing for a pembrolizumab biosimilar following Formycon/Zydus’ Biologics Licence Application for FYB206.  Formycon/Zydus announced on 13 October 2026 that the FDA had accepted for review their FYB206 BLA.

In June 2026, Samsung Bioepis claimed to be the first developer of a pembrolizumab biosimilar to announce global phase 3 trial results.  In comparison, Formycon is relying on a streamlined clinical trial pathway (without a comparative Phase 3 efficacy trial) to accelerate and support the approval of its pembrolizumab biosimilar FYB206.

Applications for approval of pembrolizumab biosimilars were filed in Korea by Samsung Bioepis (SB27) and Celltrion (CT-P51) in August 2026.  Amgen confirmed on 15 September 2026 that its Keytruda® biosimilar has successfully completed clinical trials with an FDA submission likely later in 2026.

Pembrolizumab biosimilars have reportedly been launched in Paraguay (by Bioeticos in August 2025) and approved in Vietnam (by Biocad in November 2025) and Jordan (by Sana Pharma in February 2026).  Pembrolizumab biosimilars are also in clinical trials including by mAbxience, Sandoz, Bio-Thera, Shanghai Henlius, BioNTech, Qilu Pharmaceutical and Enzene.

Boan Biotech Licenses its Denosumab Biosimilar for Japan

On 30 October 2026, China-headquartered Boan Biotech announced that it has licensed BA6101 (denosumab), biosimilar to Amgen’s Prolia® (marketed in Japan as Pralia®), to an undisclosed partner for Japan.

Under the agreement Boan Biotech’s partner has exclusive commercialisation rights to BA6101 in Japan and is responsible for regulatory submission, market access, promotion and sales of the biosimilar in the Japanese market.  Boan Biotech will receive an upfront payment, milestone payments and royalties on sales.

BA6101 (marketed as Boyoubei® in China) was approved in China in November 2022 (with BA1102 (Boluojia®), referencing Amgen’s Xgeva® (denosumab) first approved in China in 2024) and in Bolivia in January 2026.  In November 2025, Boan’s MAAs for BA6101 and BA1102 were accepted for review by the UK Medicines and Healthcare products Regulatory Agency (MHRA).  Boan Biotech submitted Biologics License Applications (BLAs) to the FDA for two denosumab biosimilars: BA6101 (denosumab 60 mg) and BA1102 (denosumab 120 mg), biosimilars to Amgen’s Prolia® and Xgeva® respectively, in May 2026.  Boan Biotech is expecting approvals in the UK and US within the next year.

Boan Biotech also intends to seek marketing authorisation for BA6101 in other countries and regions and has established a network of partners to commercialise the drug, including in the US, Southeast Asia, and Latin America.

There is one approved denosumab biosimilar in Japan to date, Alvotech/Fuji Pharma’s AVT03 (DENOSUMAB BS 120 mg/1.4 mL in a vial for subcutaneous injection; September 2025), biosimilar to Daiichi Sankyo’s Ranmark® (marketed in other countries as Amgen’s Xgeva®).  On 10 June 2026, GlycoNex announced that its denosumab biosimilar, SPD8, met the primary endpoint in a Phase 3 osteoporosis study conducted in Japan, demonstrating therapeutic equivalence to Amgen’s Prolia®.  SPD8 was co-developed by GlycoNex with Mitsubishi Gas Chemical.

Enter Pearce IP. A New Zealand Practice with IP in its DNA.

There are ways to enter a new market quietly.  And then there is the Pearce IP way.

New to New Zealand. Well Established in IP.

In less than two years, Pearce IP’s New Zealand practice has gone from new arrival to recognised player across the region’s leading independent IP rankings and directories.

Pearce IP’s New Zealand practice may be recent, but its expertise isn’t.  The team brings decades of collective experience across patent and trade mark prosecution, IP litigation, life sciences, biotechnology, pharmaceuticals, technology and commercial IP strategy.

That distinction matters.

Building an IP practice is not as simple as opening an office and putting a sign on the door.  Deep knowledge of the law is important.  Even more important is understanding the technical, commercial and regulatory environments in which our clients’ IP operates.

That is particularly true in life sciences, where a patent is rarely just a patent.

A single matter can involve scientific research, patent strategy, regulatory pathways, freedom to operate, commercialisation, competitors, litigation risk and, ultimately, the timing of bringing a product to market.Pearce IP’s specialist focus on life sciences provides its New Zealand practice with a distinctive foundation: an established specialist model brought to the New Zealand market, backed by decades of experience across Australia and New Zealand.

But specialisation is only part of the story.  The client is at the centre of the practice.

For Pearce IP, specialist expertise is not an end in itself.  It is about using that expertise to understand each client’s science, technology, commercial objectives and risk – and working collaboratively with clients as a trusted adviser and partner.

And the market has noticed.

In 2025, Pearce IP took home New Zealand Patent Prosecution Firm of the Year at the Asia IP Awards in Kuala Lumpur – a significant recognition for a practice that had entered the New Zealand market less than two years earlier.

The recognition continued into 2026, with a New Zealand Law Firm Ranking from Asia IP for Patent Prosecution – Tier 1.

In May 2026, the New Zealand firm was ranked for Patent Prosecution by IAM Patent 1000, making this recognition every year since the office opened.

The next month, Pearce IP New Zealand was ranked for Trade Mark Prosecution by Managing IP in the 2026 Asia-Pacific IP Stars.

In July, Pearce IP was named a Top Specialist Firm by Australasian Lawyer and NZ Lawyer in Intellectual Property for the second consecutive year.  It was one of only six firms ranked in intellectual property, and the only IP firm operating across both Australia and New Zealand.As Australasian Lawyer and NZ Lawyer put it, specialist firms like Pearce IP offer:

“deeper expertise, more targeted advice and greater experience in high-stakes or complex matters within their niche than generalist practices.”

Pearce IP’s New Zealand office is putting that proposition into practice.

Recognition that follows the people.

The firm’s recognition has been matched by recognition of the people behind it.  In Doyle’s Guide 2026, every Pearce IP New Zealand Executive was recognised: Paul Johns as a Leading Intellectual Property Lawyer; and Sally Paterson as a Recommended Intellectual Property Lawyer, with recently retired Julie Ballance also recognised for work completed at Pearce IP.  These results place Pearce IP alongside established New Zealand IP practices, with Pearce IP holding the equal second-highest number of rankings among firms in the guide.

For a practice with a relatively new footprint, that is a substantial recognition record in a short time.  But awards alone do not explain what is happening in New Zealand. 

WTR 1000 in 2026 was glowing in its commentary of Pearce IP:

“Despite its youth, the team at Pearce IP comprises of a “reputable and fast-growing set of expert practitioners” shaking the Trans-Tasman market. The depth and breadth of expertise across the spectrum of trademark matters have attracted some of the most eminent industrial heavyweights and blue-chip companies to the outfit…

 

Pearce IP, founded by Naomi Pearce, is a boutique firm renowned for delivering exceptional trademark services across all sectors, but with a strong focus on life sciences. The firm proudly boasts an extensive and distinguished client list that consists of domestic and overseas businesses.”

Specialist expertise in action.

At the centre of the New Zealand practice’s contentious work is Paul Johns, Lawyer, Trade Mark Attorney, and Head of Litigation – New Zealand.  Paul brings more than 24 years’ experience across New Zealand and the UK, with a background in molecular genetics and experience spanning patents, trade marks, copyright, designs, confidential information and consumer law.  His practice crosses industries from pharmaceuticals and biotechnology to animal health, med-tech, ag-tech, food and beverage technology, engineering, hospitality and entertainment.

His recognition is equally broad, including making the World IP Review (WIPR) Leaders list, Chambers Asia-Pacific, IAM Patent 1000, WTR 1000, Managing IP – IP Stars, and Doyle’s Guide.

In 2026, Asia IP recognised Paul across an extraordinary six categories in its New Zealand IP Experts list, the highest number of categories achieved by any individual in the list:

Paul Johns New Zealand IP Lawyer Attorney Award winning

⭐ Patents;

⭐ Trade Marks;

⭐ Copyright;

⭐ IP Litigation;

⭐ Media & Entertainment;

⭐ Pharma & Biotech.

WTR 1000 in 2026 says of Paul Johns;

“In the arena of disputes, executive and head of litigation Paul Johns enjoys a fantastic reputation in the market for his extensive experience in trademark disputes across various industries, handling infringement, opposition, revocation and invalidity cases, including appeals. Known for his strategic management of IP disputes, he has appeared as lead counsel in the New Zealand Court of Appeal and the High Court, and before Assistant Commissioners of Trademarks, and is a sought-after commentator on IP matters in the media.”

 

“Paul is a very experienced IP litigator. He has a pragmatic and considered business head – making sound decisions in litigation based on the best commercial outcomes for his clients.”

That breadth says something about the practice itself.  Pearce IP’s New Zealand offering is not built around a single type of IP problem.  It is built around understanding the problem from the client’s perspective – bringing together specialist expertise, strategic thinking and a focus on the commercial outcome.

The life sciences connection.

Alongside the litigation practice is Sally Paterson, a senior Trans-Tasman Patent and Trade Mark Attorney and New Zealand lawyer with more than 20 years’ experience in IP.
Sally Paterson New Zealand IP Expert

With a background in biological sciences, Sally brings particular depth in life sciences, pharmaceuticals, biotechnology and scientific and technology-driven businesses, alongside experience in patents, trade marks, designs, infringement, validity, enforceability and contentious matters.

In Doyle’s Guide 2026, Sally was recognised as a Recommended Intellectual Property Lawyer in New Zealand, one of 21 lawyers recognised in that category.

Together, Paul and Sally illustrate something fundamental about Pearce IP’s approach: technical knowledge and legal expertise are not separate pieces of the puzzle.

A lot of recognition. In a short time.

The recognition has accumulated quickly for the firm and its people – a striking result for a practice with a relatively recent New Zealand footprint.

But perhaps the more interesting question is: where did the winning model come from?

Meet the older sister. A different kind of IP firm.

If Pearce IP New Zealand is the new arrival making an impression, its older sister in Australia has been building the foundations for almost a decade.

Founded by Naomi Pearce in 2017, Pearce IP began with a deliberately specialist proposition: build an intellectual property practice around industries where scientific, technical and commercial complexity collide, whilst providing unmatched client service.

Nine years later, that proposition remains remarkably clear.

Pearce IP is not a generalist law firm that happens to do IP.  It is an independent, specialist, life sciences-focussed IP firm, working across pharmaceuticals, biopharma, biotechnology, med-tech, ag-tech and food-tech, with expertise spanning patent prosecution, litigation, trade marks, regulatory matters, freedom to operate, commercialisation, and global IP strategy.

And its specialisation is built into the firm’s DNA.

Naomi Pearce came to IP with a scientific background in molecular genetics and biochemistry, alongside qualifications in law and industrial property.  She is a registered Australian and New Zealand patent attorney and an Australian trade mark attorney, with more than 25 years’ experience in the profession.

That combination of scientific and legal expertise has shaped Pearce IP from the beginning – and provides the foundation on which the New Zealand practice has been built.

The next chapter.

The awards will continue to accrue, but the more enduring measure of Pearce IP’s New Zealand practice will be what happens between those annual announcements: the cases won, the patents secured, the brands protected, the businesses advised, the products brought to market, the disputes resolved and, ultimately, the clients whose business needs are addressed.

As IAM 1000 commented:

“Pearce IP has established itself as a go‑to outfit for life sciences mandates across Australia and New Zealand.  Combining technical depth with seasoned legal insight, the firm delivers integrated prosecution and advisory services for innovators and companies operating in pharmaceuticals, biopharmaceuticals, biotechnology, ag‑tech, food‑tech and med‑tech.  Its practitioners bring substantial scientific grounding, enabling the group to navigate complex portfolios, product lifecycles and cross‑border patent strategies with ease.  The team is also recognised for its strong collaborative culture and for fielding one of the region’s most experienced concentrations of life sciences specialists.”

For Pearce IP, the New Zealand chapter may have started with an office, but it is beginning to look like something much bigger – a specialist IP practice with its own place in the New Zealand market, backed by deep expertise, a growing track record and plenty more pages still to write.


 

 

About Pearce IP

Pearce IP is a privately owned/independent, specialist, life-sciences focussed, intellectual property/law firm offering lawyers and attorneys in Australia and New Zealand.

Our lawyers and attorneys specialise in pharma, biopharma, biotech, ag-tech, food-tech, med-tech, although our work is broader than these industries.

Pearce IP and its leaders are ranked in every notable legal directory including: Chambers & Partners, Legal 500, IAM Patent 1000, IAM Strategy 300, MIP IP Stars, Doyles Guide, WTR 1000, Best Lawyers, WIPR Leaders, Best Law Firms, among others. In 2025, Pearce IP was honoured by Australasian Lawyer and New Zealand Lawyer as a Top Specialist Firm, 5 Star Employer of Choice, and the “Standout Winner” for Inclusion and Culture (<100 employees).  

Pearce IP is the only leading IP firm in Australia and New Zealand with a female founder, and is certified by WEConnect International as women owned.

 

Pearce IP BioBlast® for the week ending 23 October 2026

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®.  Significant biosimilar activities for the week ending 23 October 2026 are set out below:


Eculizumab

On 20 October 2026, Samsung Bioepis announced that, in partnership with Brazilian state-owned pharmaceutical laboratory, Bahiafarma, and Brazilian biotechnology… Read more here.

Denosumab

On 29 September 2026, the Subject Expert Committee (SEC) under India’s Central Drugs Standard Control Organisation (CDSCO) recommended the approval of… Read more here.

Omalizumab

On 16 October 2026, Genentech and Novartis commenced BPCIA proceedings in the US District Court for the District of Delaware against Amneal Pharmaceuticals… Read more here.

Biopharma Deals

On 21 October 2026, German-headquartered Formycon announced that it has entered into a collaboration with South American company, Biocelys, to develop an… Read more here.

Biopharma News

On 13 October 2026, the FDA published its final guidance for “Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products” on the… Read more here.
 

 

On 7 October 2026, BioSpace reported that Palindrome Pharma, a new pharmaceutical company focused on biosimilar medicines, has launched in Canada… Read more here.

About Pearce IP

Pearce IP is a privately owned/independent, specialist, life-sciences focussed, intellectual property/law firm offering lawyers and attorneys in Australia and New Zealand.

Our lawyers and attorneys specialise in pharma, biopharma, biotech, ag-tech, food-tech, med-tech, although our work is broader than these industries.

Pearce IP and its leaders are ranked in every notable legal directory including: Chambers & Partners, Legal 500, IAM Patent 1000, IAM Strategy 300, MIP IP Stars, Doyles Guide, WTR 1000, Best Lawyers, WIPR Leaders, Best Law Firms, among others. In 2025, Pearce IP was honoured by Australasian Lawyer and New Zealand Lawyer as a Top Specialist Firm, 5 Star Employer of Choice, and the “Standout Winner” for Inclusion and Culture (<100 employees).  

Pearce IP is the only leading IP firm in Australia and New Zealand with a female founder, and is certified by WEConnect International as women owned.

 

Naomi Pearce

Naomi Pearce

CEO, Executive Lawyer (AU, NZ), Patent & Trade Mark Attorney (Trans Tasman)

Naomi is the CEO and Founder of Pearce IP, and is one of ANZ’s leading IP practitioners. Naomi is a market leading, strategic, commercially astute, patent lawyer, patent attorney and trade mark attorney, with over 29 years’ experience, and a background in molecular biology/biochemistry.

Ranked in virtually every notable legal directory, highly regarded by peers and clients, Naomi is renowned for her successful and elegant IP/legal strategies focussing on complex/multijurisdictional litigation, global FTO, and strategic advice.  Among other awards, Naomi is the 2026 Lexology Client Choice Winner for Patents, the 2024 Lawyers Weekly Women in Law “Executive of the Year”, the 2023 Lawyers Weekly “IP Partner of the Year”, the 2022 Lexology Client Choice Winner for Life Sciences, the 2022 Asia Pacific Women in Business Law “Patent Lawyer of the Year”, and the 2021 Lawyers Weekly Women in Law “Partner of the Year”.  Ranked in Chambers Asia Pacific, Chambers Global,  IAM Patent 1000, IAM Strategy 300, is a MIP “Patent Star”, and is recognised as a WIPR Leader for patents and trade marks.

Pearce IP is the premier life sciences focussed firm in ANZ.  Commencing in 2017. Pearce IP is the 2025 Australasian Lawyer and NZ Lawyer 5-Star Employer of Choice & “Standout Winner” for Inclusion and Culture (<100 employees).  In 2021, Pearce IP was the Lawyers Weekly Australian Law Awards IP Team of the Year.

Chantal Savage

Chantal Savage

Special Counsel, Lawyer

Chantal is an intellectual property disputes lawyer with experience advising across the spectrum of IP rights, including patents, trade marks, copyright, plant breeder’s rights and trade secrets/confidential information. Recognised as a Rising Star in IP by the Legal 500 Asia Pacific (2021-2024), Chantal has previously worked for international and top tier law firms in Australia and the United Kingdom.

With a science degree specialising in molecular biology and biochemistry, Chantal’s practice focuses particularly on complex, high-value, multi-jurisdictional patent infringement and revocation proceedings for clients in the life sciences sectors.

FDA Approves STADA/Xbrane’s Biosimilar Ranibizumab

On 27 October 2026, STADA and Xbrane Biopharma (Xbrane) announced that the FDA has approved Lucamzi™ (ranibizumab-blrz), biosimilar to Genentech’s Lucentis®, for the treatment of neovascular (wet) age-related macular degeneration and other serious eye conditions.

The approval follows Xbrane’s announcement on 3 June 2026 that the FDA had accepted its biosimilar ranibizumab BLA, which was given a Biosimilar User Fee Act (BsUFA) action date of 29 October 2026.  The ranibizumab biosimilar was co-developed by Xbrane and STADA under a 2018 agreement, and is the subject of an exclusive licensing agreement with Valorum Biologics, which will be responsible for commercialising Lucamzi™ in the US.

Xbrane resubmitted its BLA in April 2026 following an FDA Complete Response Letter (CRL) received in October 2025.  This was the second CRL issued in relation to Xbrane’s ranibizumab BLA following a first CRL in April 2024 identifying issues relating to (a) the analytical methods for the reference standard; and (b) pre-approval inspections of manufacturing partner’s sites.

A number of other ranibizumab biosimilars are approved in the US including Samsung Bioepis’ Byooviz® (September 2021, relaunched July 2026), Sandoz’s Cimerli® (August 2022, rights acquired by Sandoz from Coherus in March 2024), Formycon’s Nufymco® (December 2025) and Lupin’s Ranluspec® (June 2026).

Xbrane’s ranibizumab biosimilar has been approved in the EU and UK since November 2022, under the name Ximluci®, and was launched in the EU in April 2023.

Biocon Expands Janssen Settlement/Licence for Biosimilar Ustekinumab

On 26 October 2026, Biocon announced that it has signed a licence agreement with Janssen clearing the way for the commercialization of Yesintek™, biosimilar to Janssen’s Stelara® (ustekinumab), in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan.  Under the agreement, Biocon is permitted to commercialise Yesintek™ in the relevant countries “with immediate effect”.

Biocon first launched Yesintek™ in the US in February 2025 (in PFS and vial presentations), following Yesintek™’s original FDA approval in November 2024.  The timing of Biocon’s US launch was governed by a US settlement and licence agreement with Janssen (entered in February 2024), including to resolve an Inter Partes Review Petition.

In August 2024, Biocon announced that it had signed a patent settlement and licence agreement with Janssen for Canada, Japan, Europe and the UK.  Yesintek™ was launched in Canada in October 2025 and was approved in Europe in February 2025 and in Japan in December 2024 (announced January 2025).

Yesintek™ was approved in Australia in April 2026 and was recommended for listing on the Pharmaceutical Benefits Scheme at the July 2026 meeting of the Pharmaceutical Benefits Advisory Committee.  It is to be supplied in Australia by Biocon’s local partner Generic Health.

First Biosimilar Secukinumab Approved in China for Bio-Thera Solutions

On 26 October 2026, Bio-Thera Solutions announced that it has received marketing authorisation from China’s National Medical Products Administration (NMPA) for BAT2306 (marketed as Youzhuomei™), biosimilar to Novartis’ Cosentyx® (secukinumab).  BAT2306/Youzhuomei™ is the first biosimilar secukinumab approved in China.  According to Bio-Thera, it is also the first biosimilar secukinumab approved by any major regulatory agency in the world.

BAT2306/Youzhuomei™ is approved for psoriasis, ankylosing spondylitis and psoriatic arthritis.  Cosentyx® is approved in China for the treatment of plaque psoriasis in patients aged 6 years and older; and for psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa and non-radiographic axial spondyloarthritis in adults.

Bio-Thera completed a phase 3 clinical trial of BAT2306 in plaque psoriasis in 2024, and a phase 1 trial in 2023.  It has signed commercialisation agreements for BAT2306 with multiple partners, including Pharmapark in Russia (August 2024), Jamjoon Pharmaceuticals in Middle East and North Africa (September 2025), and Dr Reddy’s in Southeast Asia (November 2025).

Secukinumab biosimilars are also under development by Celltrion (phase 1 clinical trial completed; global phase 3 trial for CT-P55 in plaque psoriasis approved by the FDA in August 2024), Taizhou Mabtech Pharmaceutical (phase 1 trial of CMAB015 completed in 2023) and Livzon Pharmaceutical Group (phase 3 clinical trial of LZM012 in plaque psoriasis currently recruiting).  In June 2026, CSPC Pharmaceutical announced that China’s NMPA had accepted for review a marketing authorisation application for its Secukinumab Injection.

Celltrion Inks Exclusive Supply Deal with US Healthcare Company for Omalizumab & Tocilizumab Biosimilars

On 26 October 2026, Celltrion announced that its US subsidiary has signed an exclusive supply agreement with a major US healthcare company for its pre-filled syringe (PFS) formulation of Omlyclo®, biosimilar to Genentech/Novartis’ Xolair® (omalizumab), and its intravenous and subcutaneous formulations of Avtozma® (CT-P47), biosimilar to Roche’s RoActemra® (tocilizumab).  The unidentified US healthcare company owns various large hospitals, insurance companies and pharmacy benefit managers (PBMs) across the US.

Under the agreement, Omlyclo® and Avtozma® will be listed as the sole preferred products on the insurers’ formularies and supplied to affiliated medical institutions.  Insured patients who receive a prescription of either product will be able to receive treatment under their insurance coverage.  Product supply and insurance coverage began in October 2026.

Celltrion’s Omlyclo® was launched in the US in October 2026, following approval in March 2025 (75 mg/0.5ml and 150 mg/ml PFS forms) and December 2025 (300mg formulation).  Leveraging its first-mover advantage as the first omalizumab biosimilar launched in the US, Celltrion is expanding its supply channels for Omlyclo®.  In October 2026, Celltrion signed a separate supply contract for Omlyclo® with a major global US distributor.  Additionally, Celltrion is conducting formulary listing negotiations with multiple PBMs, with the contracts expected to finalise within Q4 of 2026.

Both intravenous and subcutaneous formulations of Avtozma® were first approved in the US in January 2025, with the IV formulation launched in October 2025.  In December 2025, Celltrion secured reimbursement coverage for Avtozma® IV in the US, with patient reimbursement available from January 2026.

Naomi Pearce Named Among Australia’s Patent Elite in IAM Global Leaders 2027

Pearce IP’s Founder and CEO, Naomi Pearce has again been named as one of Australia’s patent elite in the 2027 edition of IAM Global Leaders.  This is the second consecutive year that Naomi has earned a place on the list.

Inclusion in IAM Global Leaders is reserved for individuals who not only rank Gold in the IAM Patent 1000 (the leading international directory of top patent firms and practitioners), but who also, as IAM Global Leaders states,

“merit special attention – not only because of their expertise and experience related to creating, protecting, managing, transacting and enforcing critical patent rights, but also for their ability to innovate, inspire and go above and beyond to deliver value for their clients”.

Naomi was ranked Gold in both Patent Litigation and Patent Prosecution in Australia in the latest edition.

Naomi is also recognised in the IAM Strategy 300 for both Legal, and IP Management Consultancy, having maintained these rankings for the past three consecutive years.

This latest recognition builds on the achievements of Pearce IP and five of its leaders, who were recognised in the IAM Patent 1000 for 2026, with rankings across Australia and New Zealand for Patent Litigation and Patent Prosecution.

Of Naomi Pearce, the IAM Patent 1000 noted:

“At the helm is Naomi Pearce, the firm’s Founder and CEO, whose dual qualifications as an executive lawyer and patent attorney shape Pearce IP’s integrated approach to life sciences IP. With a background in molecular biology and substantial experience in both private practice and in‑house environments, she is the strategic driver behind many of the firm’s most complex patent programmes.”


 

About Pearce IP

Pearce IP is a privately owned/independent, specialist, life-sciences focussed, intellectual property/law firm offering lawyers and attorneys in Australia and New Zealand.

Our lawyers and attorneys specialise in pharma, biopharma, biotech, ag-tech, food-tech, med-tech, although our work is broader than these industries.

Pearce IP and its leaders are ranked in every notable legal directory including: Chambers & Partners, Legal 500, IAM Patent 1000, IAM Strategy 300, MIP IP Stars, Doyles Guide, WTR 1000, Best Lawyers, WIPR Leaders, Best Law Firms, among others. In 2025, Pearce IP was honoured by Australasian Lawyer and New Zealand Lawyer as a Top Specialist Firm, 5 Star Employer of Choice, and the “Standout Winner” for Inclusion and Culture (<100 employees).  

Pearce IP is the only leading IP firm in Australia and New Zealand with a female founder, and is certified by WEConnect International as women owned.

 

Formycon & Biocelys Collaborate on Undisclosed “Niche-Buster” Biosimilar, FYB286

On 21 October 2026, German-headquartered Formycon announced that it has entered into a collaboration with South American company, Biocelys, to develop an undisclosed biosimilar, FYB286.  Formycon refers to the biosimilar as a “niche buster”, a drug for a rare condition with global annual sales in the low- to mid-single-digit billion-dollar range.

The collaboration is aimed at combining Formycon’s experience in biosimilar development with Biocelys’ state-of-the-art manufacturing infrastructure.  Formycon expects demand for FYB286 to increase substantially, particularly in emerging markets, presenting an attractive market opportunity.

Biocelys is indirectly controlled by ATHOS KG, which is Formycon’s largest shareholder.  The project is being financed upfront by Santo Biosimilar GmbH, an affiliated company of ATHOS.  Under the agreement with Santo, Formycon will receive arm’s-length compensation for its development services and will participate in future revenues of Santo with a low double-digit percentage share.  The co-operation agreement between Formycon and Biocelys covers joint development, manufacture, regulatory approval and supply management of FYB286.

Alvotech/Dr Reddy’s Biosimilar Denosumab PFS Recommended in India

On 29 September 2026, the Subject Expert Committee (SEC) under India’s Central Drugs Standard Control Organisation (CDSCO) recommended the approval of Alvotech/Dr Reddy’s Laboratories’ 120 mg/1 mL denosumab, biosimilar to Amgen’s Xgeva®, in a pre-filled syringe (PFS) with an automatic needle guard.  This new presentation expands Alvotech/Dr Reddy’s denosumab portfolio in India, following the approval of its denosumab vial presentation (120 mg/1.7 mL solution for injection) in August 2017.

The approval is conditional on Dr Reddy’s Laboratories submitting an active post-marketing surveillance study protocol for the approved indications within three months and conducting the study in India and adding product label warnings for patients with phenylketonuria regarding the presence of phenylalanine in the product.

Dr Reddy’s and Alvotech entered into a licence and supply agreement in May 2024 for the commercialisation of AVT03 (denosumab), under which Alvotech develops and manufactures the product and Dr Reddy’s commercialises it exclusively in the US, and semi-exclusively in the EU and UK.

Alvotech also has semi-exclusive commercialisation agreements for European markets with STADA (June 2024) in relation to AVT03.  STADA will market AVT03 as Kefdensis® (referencing Amgen’s Prolia®) and Zvogra® (referencing Xgeva®), while Dr. Reddy’s will market AVT03 as Acvybra® (referencing Prolia®) and Xbonzy® (referencing Xgeva®).

Pearce IP BioBlast® for the week ending 16 October 2026

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®.  Significant biosimilar activities for the week ending 16 October 2026 are set out below:


Aflibercept

On 14 October 2026, Alvotech and Advanz Pharma announced they have submitted an application to the European Medicines Agency for AVT29, biosimilar to… Read more here.

Nivolumab

On 18 October 2026, the Economic Times reported that Lupin has received marketing approval from India’s Central Drugs Standard Control Organisation (CDSCO)… Read more here.

 

On 13 October 2026, Xbrane Biopharma announced that patient enrolment has completed for a clinical trial of Xdivane™, Xbrane’s biosimilar to BMS’ Opdivo®… Read more here.

Ocrelizumab

On 15 October 2026, Biocad announced that the Russian Ministry of Health has approved biosimilar ocrelizumab (BCD-281) under the name Ocrelizumab Biocad®… Read more here.

Pembrolizumab

On 13 October 2026, Formycon and Zydus Lifesciences announced that the FDA has accepted for review their Biologics Licence Application for FYB206, biosimilar… Read more here.

Pertuzumab

On 14 October 2026, Biocon announced that it has entered a global settlement and licence agreement with Genentech for Pebrilzo® (Bmab 1500), biosimilar to… Read more here.

Ranibizumab, Filgrastim

On 16 October 2026, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) announced the outcomes of its October 2026… Read more here.

About Pearce IP

Pearce IP is a privately owned/independent, specialist, life-sciences focussed, intellectual property/law firm offering lawyers and attorneys in Australia and New Zealand.

Our lawyers and attorneys specialise in pharma, biopharma, biotech, ag-tech, food-tech, med-tech, although our work is broader than these industries.

Pearce IP and its leaders are ranked in every notable legal directory including: Chambers & Partners, Legal 500, IAM Patent 1000, IAM Strategy 300, MIP IP Stars, Doyles Guide, WTR 1000, Best Lawyers, WIPR Leaders, Best Law Firms, among others. In 2025, Pearce IP was honoured by Australasian Lawyer and New Zealand Lawyer as a Top Specialist Firm, 5 Star Employer of Choice, and the “Standout Winner” for Inclusion and Culture (<100 employees).  

Pearce IP is the only leading IP firm in Australia and New Zealand with a female founder, and is certified by WEConnect International as women owned.

 

Naomi Pearce

Naomi Pearce

CEO, Executive Lawyer (AU, NZ), Patent & Trade Mark Attorney (Trans Tasman)

Naomi is the CEO and Founder of Pearce IP, and is one of ANZ’s leading IP practitioners. Naomi is a market leading, strategic, commercially astute, patent lawyer, patent attorney and trade mark attorney, with over 29 years’ experience, and a background in molecular biology/biochemistry.

Ranked in virtually every notable legal directory, highly regarded by peers and clients, Naomi is renowned for her successful and elegant IP/legal strategies focussing on complex/multijurisdictional litigation, global FTO, and strategic advice.  Among other awards, Naomi is the 2026 Lexology Client Choice Winner for Patents, the 2024 Lawyers Weekly Women in Law “Executive of the Year”, the 2023 Lawyers Weekly “IP Partner of the Year”, the 2022 Lexology Client Choice Winner for Life Sciences, the 2022 Asia Pacific Women in Business Law “Patent Lawyer of the Year”, and the 2021 Lawyers Weekly Women in Law “Partner of the Year”.  Ranked in Chambers Asia Pacific, Chambers Global,  IAM Patent 1000, IAM Strategy 300, is a MIP “Patent Star”, and is recognised as a WIPR Leader for patents and trade marks.

Pearce IP is the premier life sciences focussed firm in ANZ.  Commencing in 2017. Pearce IP is the 2025 Australasian Lawyer and NZ Lawyer 5-Star Employer of Choice & “Standout Winner” for Inclusion and Culture (<100 employees).  In 2021, Pearce IP was the Lawyers Weekly Australian Law Awards IP Team of the Year.

Chantal Savage

Chantal Savage

Special Counsel, Lawyer

Chantal is an intellectual property disputes lawyer with experience advising across the spectrum of IP rights, including patents, trade marks, copyright, plant breeder’s rights and trade secrets/confidential information. Recognised as a Rising Star in IP by the Legal 500 Asia Pacific (2021-2024), Chantal has previously worked for international and top tier law firms in Australia and the United Kingdom.

With a science degree specialising in molecular biology and biochemistry, Chantal’s practice focuses particularly on complex, high-value, multi-jurisdictional patent infringement and revocation proceedings for clients in the life sciences sectors.

Samsung Bioepis Enters 10-Year Exclusive Deal to Supply Biosimilar Eculizumab in Brazil

On 20 October 2026, Samsung Bioepis announced that, in partnership with Brazilian state-owned pharmaceutical laboratory, Bahiafarma, and Brazilian biotechnology company, Bionovis, it has signed an exclusive partnership agreement to supply SB12, biosimilar to Alexion’s Soliris® (eculizumab), to Brazil’s universal public health system.

The agreement is formed under Brazil’s strategic Productive Development Partnership (PDP) framework.  Under the PDP program, Samsung Bioepis will have exclusive access to Brazil’s public healthcare market to supply eculizumab over a 10-year period form 2027.  During this period, Samsung Bioepis will also transfer technology to its local partners, enabling manufacturing in Brazil.

SB12 was approved in Brazil in December 2024 for the treatment of adults and children with PNH and atypical haemolytic uremic syndrome (aHUS).  It was the second eculizumab biosimilar launched in the US (where it is marketed by Teva as Epysqli®) in April 2025, following the launch of Amgen’s Bkemv® in March 2025.  Epysqli® launched in Germany, Italy and Spain in October 2023 and in Korea in April 2024.

Since 2019, Samsung Bioepis has supplied more than 6 million units of its etanercept and trastuzumab biosimilars in Brazil through the PDP program.  In September 2026, Biocon entered into a supply deal with the Brazilian government to supply Bmab 1500, biosimilar to Roche/Genentech’s Perjeta® (pertuzumab) under the PDP program.

BioBlast® Editor and Contributing Author

Naomi Pearce & Emily Bristow

Naomi Pearce & Emily Bristow

Editor: Naomi Pearce, Executive Lawyer, Patent Attorney & Trade Mark Attorney
Contributing Author: Emily Bristow, Law Graduate

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.